In summary, our study indicated that blocking TREK-1 alleviates depressive and anxiety-like behaviors of CUMS rats and hinders A1-like astrocyte activation by suppressing the NF-κB pathway in MDD via in vivo as well as in vitro studies (Fig. 8). Here, NFKB1 is linked to major depressive disorder.